Press releases

Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019

Sanofi delivered solid growth in Q2 2019

Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon

Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer

Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care

Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma

Sanofi : Availability of the Pre-quarterly Results Communication

Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union